// App-Quantinova.ai

: Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing's disease (CD)

Researchers

Presenter

  • John Newell-Price

Principal Investigators

  • Rosario Pivonello

  • Antoine Tabarin

  • Maria Fleseriu

  • Przemysław Witek

  • Manica Gadelha

  • Stephan Petersenn

  • Libuse Tauchmanova

  • Shoba Ravichandran

  • Michael Roughton

  • Andre Lacroix

  • Beverly MK Biller

Medical Centers

  • Medical School, University of Sheffi eld, Sheffi eld, UK

  • Universita Federico II di Napoli, Napoli, Italy

  • Department of Endocrinology, CHU of Bordeaux, Bordeaux, France

  • Northwest Pituitary Center, Oregon Health & Science University, Portland, OR

  • Department of Gastroenterology, Endocrinology and Internal Diseases, Military Institute of Medicine, Warsaw, Poland

  • Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

  • ENDOC Center for Endocrine Tumors, Hamburg, Germany

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA

Locations

  • United Kingdom

  • Italy

  • France

  • United States

  • Poland

  • Brazil

  • Germany

  • Switzerland

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • N/A

Biomarkers

  • Cortisol

Drug/Treatment

  • Pasireotide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved